Polaris Market Research today announced findings from its latest report, projecting the U.S. ATP assays market to grow from USD 1.08 billion in 2024 to USD 1.54 billion by 2034, at a CAGR of 3.60%. The report profiles 10 leading companies across three key market segments, covering type, application, and end use. ATP (adenosine triphosphate) assays are biochemical tests that measure the presence and amount of ATP, the primary energy carrier in living organisms, most commonly through a bioluminescence reaction in which the luciferase enzyme emits light proportional to ATP concentration, allowing researchers to gauge metabolic activity, cell viability, or microbial contamination.

Analyst Commentary on U.S. ATP Assays Market Growth

"ATP assays have become the workhorse test for measuring cell viability, and as drug pipelines grow and cancer research accelerates, that workhorse role only gets bigger," said a senior analyst at Polaris Market Research. "For buyers and investors, the most interesting growth sits in cell-based assays, where rising demand for cytotoxicity and cell-viability testing in precision medicine is outpacing the broader market.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/us-atp-assays-market

U.S. ATP Assays Market Statistics at a Glance

• 2024 Market Size: USD 1.08 Billion
• 2025 Market Size: USD 1.12 Billion
• 2034 Projected Size: USD 1.54 Billion
• CAGR (2025–2034): 3.60%
• Largest Segment (2024): Luminometric ATP Assays, by Type

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Expanding healthcare expenditure, ongoing cancer research, and growing use of ATP assays in drug discovery and cytotoxicity testing are the primary forces behind the market's expansion, alongside rising demand for food safety and quality testing. Research institutions and pharmaceutical companies are expanding efforts to discover novel cancer therapies, where ATP assays play a key role in screening and validating potential anti-cancer compounds by quickly determining the metabolic activity of cancer cells and their response to chemotherapy and targeted treatments. According to the Centers for Disease Control and Prevention, an estimated 129 million people in the U.S. had at least one major chronic disease as of February 2024, a burden that is pushing researchers and clinicians toward ATP-based tools for measuring cellular viability and treatment efficacy.

Major Companies Covered: Abcam plc, Becton, Dickinson and Company (BD), Biomerieux SA, Danaher Corporation, Merck KGaA, Lonza Group Ltd., PerkinElmer Inc., Promega Corporation, Quest Diagnostics Incorporated, and Thermo Fisher Scientific.

Segments Covered: By Type (Luminometric ATP Assays, Enzymatic ATP Assays, Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, Cell-Based ATP Assays, Others), By Application (Drug Discovery and Development, Clinical Diagnostics, Environmental Testing, Food Safety and Quality Testing, Others), and By End Use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospital and Diagnostics Laboratories).

Recent Developments in the U.S. ATP Assays Market

• March 2025: Biotium, a provider of fluorescent reagents and kits for life science research, announced the release of its Steady-ATP HTS Viability Assay Kit for assessing cell proliferation, expanding the range of high-throughput screening tools available to researchers.

U.S. Market Snapshot: Pharma and Biotech Lead, Hospitals Fastest-Growing

Luminometric ATP assays held the largest share by type in 2024, owing to their high sensitivity, rapid results, and widespread adoption across microbiology, oncology, and drug discovery applications, while the drug discovery and development segment dominated by application as pharmaceutical and biotechnology companies extensively used the assays to assess cell viability and cytotoxic effects during preclinical research. By end use, pharmaceutical and biotechnology companies accounted for the largest share in 2024 given their extensive use of ATP-based bioluminescence in drug discovery, preclinical development, and quality control, while hospital and diagnostics laboratories are expected to grow fastest through 2034 as demand rises for rapid microbial contamination detection and treatment-efficacy monitoring. According to the American Medical Association, U.S. health spending increased by 7.5% in 2023 to USD 4.9 trillion, a trend that continues to fund expanded assay adoption across research and clinical settings.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the top U.S. ATP assay companies and market forecast through 2034, the underlying report benchmarks market share, company positioning, and segment-level forecasts across type, application, and end use to support sourcing, partnership, and investment decisions. With luminometric assays and drug-discovery applications commanding the largest current revenue, and cell-based assays and hospital laboratories positioned as the fastest-growing categories, buyers gain a clear view of where near-term demand is concentrated and where future investment in cell-viability and point-of-care contamination testing is likely to accelerate.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

probiotics-market

neuromarketing-market

why-the-2026-memory-shortage-is-reshaping-ai-chip-supply-chains

superfoods-market

global-optical-coherence-tomography-oct-market

global-solar-tracker-market

aluminum-foil-market

pharmacy-benefit-management-market

wood-coatings-market